地址:武汉市洪山区光谷大道35号光谷总部国际时代 二期1栋1301
电话:18995651644
传真:15172469628
邮箱:sales@amyjet.com

艾美捷科技代理Biorelevant品牌。
Biorelevant公司成立于2006年,位于英国伦敦,是一家专注于开发和生产模拟人体胃肠道环境的体外溶出介质的公司,致力于为制药行业提供更准确、更可靠的药物溶出测试解决方案。Biorelevant公司可提供体外溶出介质:包括多种模拟人体胃肠道环境的溶出介质,用于药物溶出测试;还可以根据客户需求,提供定制化的溶出介质和测试方案并提供全面的技术支持和应用指导,帮助客户优化药物开发和测试流程。Biorelevant产品包括:FaSSIF、FeSSIF、FaSSGF、FeSSGF等多种模拟空腹和饱腹状态的溶出介质。其产品应用范围包括:
(1)药物开发,广泛应用于口服固体制剂的开发和优化,提高生物利用度和疗效;
(2)质量控制,用于药物生产过程中的质量控制,确保产品的一致性和稳定性;
(3)法规提交,支持药物注册和法规提交,提供符合监管要求的溶出测试数据。
<<<< " data-original="http://plant.51antibodies.com/template/company/xys_lvse/skin/image/lazyLoad.jpg" alt="艾美捷科技代理Biorelevant品牌"> 艾美捷科技代理Biorelevant品牌
invivoCrown IV0113替换BioXCell BE0075
invivoCrown IV0117替换BioXCell BE0223
<艾美捷科技代理Helvetica Health Care品牌全系列产品
Helvetica Health Care是一家位于瑞士日内瓦的医疗保健公司,致力于通过创新的产品和技术来管理健康和提高生活质量。作为瑞士生物技术协会的成员,Helvetica Health Care通过了ISO 13485认证,在质量和创新方面坚持最高标准。涵盖各种质量控制和验证面板,适用于不同的分子测试平台和检测。这些产品有多种规格,可用于单一或多种分析物的检测,帮助实验室监控测试性能,确保测试的准确性和可靠性。其质量控制和验证组合可根据产品配置、填充量和分析物浓度进行定制,满足不同平台的需求。
▎Helvetica Health Care产品线
Helvetica Health Care公司的产品涵盖:抗体、生命科学产品、血液分离产品、临床/诊断样本、质控品与标准品、分子生物学产品、细胞因子与生长因子、ELISA试剂盒/Western印迹相关产品、微生物、氧化应激产品、诊断产品以及人血浆制品。

▎Helvetica Health Care部分产品列表
| 货号 | 产品描述 |
| NATFRC-6C | NATtrol Flu/RSV/SARS-CoV-2 Positive Control (6 x 0.5mL) |
| NATCV9-6C | NATtrol Flu/RSV/SARS-CoV-2 Negative Control (6 x 0.5mL) |
| NATRPC2.1-BIO | NATtrol Respiratory Panel 2.1 (RP2.1) Controls (12 x 0.3mL) |
| NATRVP2.1-BIO | NATtrol Respiratory Verification Panel 2.1 (24 x 0.6mL) (EA) |
| NATRVP2.1-BIO Plus | NATtrol Respiratory Verification Panel 2 Plus (+NATCOV(MR)-BIO) (24x 0.6 ml + 1x 0.6 ml) |
| NATRVP2-QIA | NATtrol Respiratory Verification Panel 2 (21 x 0.25mL) (EA) |
| NATSARS(COV2)-VP | NATtrol SARS-CoV-2 Variant Panel (4 x 0.5mL) |
| NATSARS(COV2)-ERC | SARS-Related Coronavirus 2 (SARS-CoV-2) External Run Control (6 x 0.5 mL) |
| NATSARS(COV2)-ERC1 | NATtrol SARS-Related Coronavirus 2 (SARS-COV-2) Positive Control (6x 1.0 ml) |
| NATSARS(COV2)-NEG | SARS-Related Coronavirus 2 (SARS-CoV-2) Negative Control (6 x 0.5 mL) |
| NATSARS(COV2)-NEG1 | NATtrol SARS-Related Coronavirus 2 (SARS-COV-2) Negative Control (6x 1.0 ml) |
| NATSARS(COV2)-ST | SARS-Related Coronavirus 2 (SARS-CoV-2) Stock |
| NATSARS(COV2-SA)-ST | NATtrol SARS-Related Coronavirus 2 (SARS-CoV-2) Variant B.1.351 Stock (1mL) |
| NATSARS(COV2-UK)-ST | NATtrol SARS-Related Coronavirus 2 (SARS-CoV-2) Variant B.1.1.7 Stock (1mL) |
| 0810229-0.5mg | Coronavirus 229E Lysate (0.5 mg) |
| 0810587 | SARS-CoV-2 (Isolate: USA-WA1/2020) Lysate (1 mg) |
| 0810587-0.5mg | SARS-CoV-2 (Isolate: USA-WA1/2020) Lysate (0.5 mg) |
| 0810587CFHI-0.5mL | SARS-CoV-2 (Isolate: USA-WA1/2020) Culture Fluid (Heat Inactivated) (0.5 mL) |
| 0810587CFHI | SARS-CoV-2 (Isolate: USA-WA1/2020) Culture Fluid (Heat Inactivated) (1.0 mL) |
| 0810587UV | SARS-CoV-2 (Isolate: USA-WA1/2020) Culture Fluid (UV Inactivated) (1 mL) |
| 0810589CFHI | SARS-CoV-2 (Isolate: Italy-INMI1) Culture Fluid (Heat Inactivated) (1 mL) |
| 0810589UV | SARS-CoV-2 (Isolate: Italy-INMI1) Culture Fluid (UV Inactivated) (1 mL) |
| 0810590CFHI | SARS-CoV-2 (Isolate: Hong Kong/VM20001061/2020) Culture Fluid (Heat Inactivated) (1 mL) |
| 0810590UV | SARS-CoV-2 (Isolate: Hong Kong/VM20001061/2020) Culture Fluid (UV Inactivated) (1 mL) |
| 0810617UV | SARS-CoV-2 Lineage P1_2021; Gamma Variant (NY-Wadsworth-21033899-01/2021) Culture Fluid (UV)) |
| 0810618UV | SARS-CoV-2 Lineage P2_2021; Zeta Variant (NY-Wadsworth-21006055-01/2021) Culture Fluid (UV) |
| 0810619UV | SARS-CoV-2 Iso1 Lin B.1.526_2021 Iota (NY-Wadsworth-21025952-01/2021) CF (UV Inactivated) |
| 0810620UV | SARS-CoV-2 Iso2 Lin B.1.526_2021 Iota (NY-Wadsworth-21025952-01/2021) CF (UV Inactivated) |
| 0810621UV | SARS-CoV-2 Lineage B.1_2020 (NY-Wadsworth-103677-01/2020) CF (UV Inactivated) |
| 0810622UV | SARS-CoV-2 Lineage B.1.595_2020 (NY-Wadsworth-33126-01/2020) CF (UV Inactivated) |
| 0810612CFHI | SARS-CoV-2 Variant B.1.1.7 (Isolate:USA/CA_CDC_5574/2020) Culture Fluid (Heat Inactivated) (1 mL) |
| 0810612UV | SARS-CoV-2 Lineage B.1.1.7; Alpha Variant (USA/CA_CDC_5574/2020) CF (UV Inactivated) (1 mL) |
| 0810613CFHI | SARS-CoV-2 Variant B.1.351(Isolate:South_Africa/KRISP-K005325/2020) CF (Heat Inactivated) (1 mL) |
| 0810613UV | SARS-CoV-2 Lineage B.1.351; Beta (South_Africa/KRISP-K005325/2020) CF (UV Inactivated) (1 mL) |
| 0810614CFHI | SARS-CoV-2 Variant B.1.1.7 (Isolate:England/204820464/2020) Culture Fluid (Heat Inactivated) (1 mL) |
| 0810614UV | SARS-CoV-2 Lineage B.1.1.7 Alpha Variant (England/204820464/2020) CF (UV Inactivated) (1 mL) |
| 0810616CFHI | SARS-CoV-2 Lineage P1; Gamma Variant (Japan/TY7-503/2021) CF (Heat Inactivated) (1 mL) |
| 0810616UV | SARS-CoV-2 Lineage P1; Gamma Variant (Isolate: Japan/TY7-503/2021) CF (UV Inactivated) (1 mL) |
| 0810617CFHI | SARS-CoV-2 Lineage P1_2021; Gamma Variant (NY-Wadsworth-21033899-01/2021) – CFHI (1.0 ml) |
| 0810618CFHI | SARS-CoV-2 Lineage P2_2021; Zeta Variant (NY-Wadsworth-21006055-01/2021) – CFHI (1.0 ml) |
| 0810619CFHI | SARS-CoV-2 Lso1 Lin B.1.526_2021 Lota (NYWadsworth-21025952-01/2021) – CFHI (1.0 ml) |
| 0810620CFHI | SARS-CoV-2 Lso2 Lin B.1.526_2021 Lota (NYWadsworth-21025952-01/2021) – CFHI (1.0 ml) |
| 0810621CFHI | SARS-CoV-2 Lineage B.1_2020 (NY-Wadsworth-103677-01/2020) – CFHI (1.0 ml) |
| 0810622CFHI | SARS-CoV-2 Lineage E3.1.595J2020 (NYWadsworth-33126-01/2020) – CFHI (1.0 ml) |
| 0810623UV | SARS-CoV-2 Lineage B.1.617.1 Kappa Variant (USA/CA-Stanford-15_S02/2021) CF (UV Inactivated) |
| 0810623CFHI | SARS-CoV-2 Lineage B.1.617.1 Kappa Variant (USA/CA-Stanford-15_S02/2021) CF (Heat Inactivated) |
| 0810624UV | SARS-CoV-2 Lineage B.1.617.2; Delta Variant (USA/PHC658/2021) CF (UV Inactivated) |
| 0810624CFHI | SARS-CoV-2 Lineage B.1.617.2; Delta Variant (USA/PHC658/2021) CF (Heat Inactivated) |
| 0820010CFHI | VeroE6 Culture Fluid (Heat Inactivated) (1 mL) |
| 0801043 | Goat Anti-SARS-CoV-2 Polyclonal Serum (0.5 ml) |
| 0831042 | SARS-CoV-2 (recombinant) Stock (1 x 1.0 mL) |
| 0831043 | SARS-CoV-2 (E/ORF1ab recombinant) Stock (1 x1.0mL) |
| NATSARS-ST | Coronavirus SARS Stock (Qualitative) (1 mL) |
| NATCOV(229E)-ST | Coronavirus 229E Stock (Qualitative) (1 mL) |
| 0810229CFHI | Coronavirus (Strain: 229E) Culture Fluid (Heat Inactivated) (1 mL) |
| 0810229 | Coronavirus Strain: 229E Lysate |
| 0810229UV | Coronavirus (Strain: 229E) Culture Fluid (UV Inactivated) (1 mL) |
| NATCOV(NL63)-ST | Coronavirus NL63 Stock (Qualitative) (1 mL) |
| 0810228CFHI | Coronavirus (Strain: NL63) Culture Fluid (Heat Inactivated) (1 mL) |
| 0810228 | Coronavirus Strain: NL63 Lysate |
| 0810228UV | Coronavirus (Strain: NL63) Culture Fluid (UV Inactivated) (1 mL) |
| NATCOV(OC43)-ST | Coronavirus OC43 Stock (Qualitative) (1 mL) |
| 0810024CFHI | Coronavirus (Strain: OC43) Culture Fluid (Heat Inactivated) (1 mL) |
| 0810024 | Coronavirus Strain: OC43 Lysate |
| NATMERS-ST | MERS-CoV Stock (Qualitative) (1 mL) |
| NATMR-BIO | NATtrol MERS Recombinant Pack (2x 0.2 ml +0.5 ml) |
| NATCOV(MR)-BIO | NATtrol MERS-S. Cerevisiae (0.6 ml) |
| 0810575 | MERS-COV (Strain: Florida/USA-2_Saudi Arabia_2014) Lysate(1mg) |
| 0810575-0.5mg | MERS-COV (Strain: Florida/USA-2_Saudi Arabia_2014) Lysate(0.5mg) |
| CV033122 | COVID-19 Cross Over Panel (40x 1.0 ml) |
invivoCrown IV0114替换BioXCell BE0213
invivoCrown IV0102替换BioXCell BE0003-1
invivoCrown IV0108替换BioXCell BE0034

艾美捷科技代理InSCREENeX品牌全系列产品
InSCREENeX GmbH成立于2009年,位于德国布伦瑞克亥姆霍兹感染研究中心内,是一家专注于开发细胞筛选技术的德国生物技术公司,InSCREENeX生产用于药物开发的细胞系统。InSCREENeX在该领域拥有超过15年的哺乳动物细胞基因修饰专业知识,在此期间成功开发了SCREENflex和CI-SCREEN这两项高度创新的技术。
利用SCREENflex技术,可以根据客户需求创建稳定的重组哺乳动物细胞。这种方法具有以下优势:快速建立所需的测试系统、目标基因的稳定表达,以及能够以不同水平调控该基因的表达。SCREENflex 技术具有普适性,已成功应用于建立多种蛋白质类别,例如 GPCRs(G蛋白偶联受体)、离子通道、抗体和细胞因子。InSCREENeX公司的产品包括稳定表达细胞系、永生化细胞系以及细胞培养试剂。

▍InSCREENeX产品线
● 稳定表达细胞系:包括离子通道、GPCRs、整合素及其他受体的稳定过表达细胞系
| 品名 | 货号 | Target | Cell background |
| CHO-Nav1.8 | INS-SF-1003 | human Nav1.8 plus beta subunit 1 | CHO |
| CHO-Nav1.7 | INS-SF-1037 | human Nav1.7 | CHO |
| CHO-PD-L1 | INS-SF-1028 | human PD-L1 | CHO |
| CHO-EpCAM | INS-SF-1027 | human EpCAM | CHO |
| CHO-PDCD1 | INS-SF-1026 | human PDCD1 | CHO |
| CHO-BCMA | INS-SF-1025 | human BCMA | CHO |
| CHO-B7H3 | INS-SF-1019 | B7H3 | CHO |
| HEK293-CTLA4 | INS-SF-1014 | CTLA4 | HEK293 |
| CHO-CTLA4 | INS-SF-1013 | CTLA4 | CHO |
| HEK293-CXCR4 | INS-SF-1006 | CXCR4 | HEK293 |
| CHO-CXCR4 | INS-SF-1004-L | CXCR4 | CHO |
| CHO-CXCR4 | INS-SF-1004-MH | CXCR4 | CHO |
| HEK293-CXCR7 | INS-SF-1009 | CXCR7 | HEK293 |
| CHO-CXCR7 | INS-SF-1007-L | CXCR7 | CHO |
| CHO-CXCR7 | INS-SF-1007-MH | CXCR7 | CHO |
| HEK293-FOLR1 | INS-SF-1018 | FOLR1 | HEK293 |
| CHO-FOLR1 | INS-SF-1017 | FOLR1 | CHO |
| HEK293-HER2 | INS-SF-1012 | HER2 | HEK293 |
| CHO-HER2 | INS-SF-1010-MH | HER2 | CHO |
| CHO-HER2 | INS-SF-1010-H | HER2 | CHO |
| HEK293-TACD2 | INS-SF-1016 | TACD2 | HEK293 |
| CHO-TACD2 | INS-SF-1015 | TACD2 | CHO |
| HEK293-FAP | INS-SF-1001 | FAP | HEK293 |
| HEK293-CCR8 | INS-SF-1024 | CCR8 | HEK293 |
| CHO-CCR8 | INS-SF-1023 | CCR8 | CHO |
● 永生化细胞系:来自不同物种的功能性永生化细胞系。
| 品名 | 货号 | Species | Organ/Tissue |
| CI-pNaEC | INS-CI-1029 | porcine | Nasal epithel |
| CI-muMEC | INS-CI-1004 | murine | Vascular endothel |
| CI-muHepa | INS-CI-1012 | murine | Liver, hepatocytes |
| CI-muINTEPI | INS-CI-1007 | murine | Intestinal epithel (fetal) |
| CI-muADINTESTI | INS-CI-1018 | murine | Intestinal epithel (adult) |
| CI-huThyrEC | INS-CI-1017 | human | Thyroid epithel |
| CI-huVEC | INS-CI-1002 | human | Endothel, Umbilical vein |
| CI-huOB | INS-CI-1005 | human | Osteoblasts |
| CI-huMEC | INS-CI-1008 | human | Microvascular endothel |
| CI-huFIB | INS-CI-1010 | human | Fibroblasts |
| CI-huEGC | INS-CI-1030 | human | Enteric glial cells (intestine) |
| CI-huBroBEC | INS-CI-1025 | human | Lung, bronchial epithel |
| CI-hAELVi | INS-CI-1015 | human | Lung, Alveoli |
| CI-huArlo | INS-CI-1031 | human | Lung, Alveoli |
● Reagents and Consumables产品
| 分类 | 品名 | 货号 | 规格 |
| Culture Media | CHO Growth Medium A | INS-ME-1039 | 500 ml |
| Culture Media | CHO Growth Medium B | INS-ME-1040 | 500 ml |
| Culture Media | FasTEER Medium | INS-ME-1032-100 | 100 ml |
| Culture Media | HEK293 Growth Medium A | INS-ME-1041 | 500 ml |
| Culture Media | huAEC Medium | INS-ME-1013-100 | 100 ml |
| Culture Media | huAEC Medium | INS-ME-1013-500 | 500 ml |
| Culture Media | huBroBEC Medium | INS-ME-1033 | 500 ml |
| Culture Media | huEGC Medium | INS-ME-1027 | 500 ml |
| Culture Media | huFIB Medium | INS-ME-1001 | 500 ml |
| Culture Media | huMEC Medium | INS-ME-1012 | 500 ml |
| Culture Media | huOB Differentiation Medium | INS-ME-1007 | 100 ml |
| Culture Media | huOB Maintenance Medium | INS-ME-1006 | 500 ml |
| Culture Media | huThyrEC Medium | INS-ME-1017 | 500 ml |
| Culture Media | huVEC Medium | INS-ME-1011 | 500 ml |
| Culture Media | muADINTESTI Medium | INS-ME-1023 | 500 ml |
| Culture Media | muINTEPI Medium | INS-ME-1005 | 500 ml |
| Culture Media | muMEC Medium | INS-ME-1004 | 500 ml |
| Culture Media | pNaEC Medium | INS-ME-1038 | 500 ml |
| Coating Solutions | Coating Solution | INS-SU-1026 | 50ml;100ml;300ml |
| Freezing Media | Cell Freezing Medium | INS-SU-1027 | 30 ml |
▍InSCREENeX提供的服务
● Landing Pad Cells:将目标单拷贝整合到CHO、HEK293 和 Llama主细胞系中,快速生成细胞系并进行变体库整合。
● Random Integration:通过病毒或非病毒方法将目标基因随机整合到任何细胞系中。
● Cell culture services:高度定制化的细胞系服务,包括细胞库构建、细胞存储、制备:细胞沉淀(Pellets)、细胞裂解液(Lysates)、DNA、RNA、培养基优化,原代细胞分离与分选等。
● Assay services:建立并运行检测方法,包含检测方法建立与优化,代运行检测服务等。
● Molecular biology services:包含克隆构建,质粒制备,DNA/RNA分离提取与制备,慢病毒生产等服务。
" data-original="http://plant.51antibodies.com/template/company/xys_lvse/skin/image/lazyLoad.jpg" alt="艾美捷科技代理InSCREENeX品牌全系列产品"> 艾美捷科技代理InSCREENeX品牌全系列产品
invivoCrown IV0102替换BioXCell BE0003-1
地址:武汉市洪山区光谷大道35号光谷总部国际时代 二期1栋1301
电话:18372041646
传真:17754422825
邮箱:sales@amyjet.com
0.0641